olivLaw · US equity research
Galapagos NV LKFT
Pharmaceutical Preparations · SIC 2834 · Vertical: Pharmaceutical Preparations (SIC 2834)
Galapagos NV is a Belgian biotechnology company redirecting its activity after deciding to wind down its cell therapy operations and focus on acquisitions and development partnerships. The timing matters because 2025 revenues were dominated by the release of deferred income from the Gilead agreement, while the company now relies on a sizeable financial portfolio and a single remaining clinical program, GLPG3667.
The AI analysis may be outdated: new filings came after its sources (see the «AI analysis» section).
At the close of 04 Nov 2026, Galapagos NV (LKFT) stock was 34.09 USD (+6.03% on the day), with beta 0.52, 52-week range 26.08–34.64 USD.
Data as of · AI analysis dated · Source: SEC filings and closing prices, computed by olivLaw.
Price history
Loading chart…
Technical reading
- RSI (14)
- 77.3
- overbought (≥ 70)
- Bollinger (20, 2)
- 28.36 – 33.61
- above the upper band · %B 1.09 · band width 17.0%
- SMA 50 / 200
- 29.70 / 29.92
- mixed trend
- MACD (12, 26, 9)
- 0.94 / 0.74
- MACD above signal
Indicators describe past prices; on their own they do not predict direction. On our history the RSI ≤ 40 filter added no return (see the signals methodology).
Performance
| Company | S&P 500 | vs S&P 500 | Vertical median | |
|---|---|---|---|---|
| 1 month | +15.5% | −1.1% | +16.6 pp | — |
| 3 months | +30.7% | −0.5% | +31.2 pp | — |
| 6 months | +18.3% | +4.4% | +13.9 pp | — |
| Year to date | +4.3% | +12.3% | −8.1 pp | — |
| 1 year | +11.9% | +13.5% | −1.6 pp | −9.2% |
| 3 years | −8.0% | +76.4% | −84.4 pp | +50.7% |
| 5 years | −37.2% | +63.7% | −100.9 pp | — |
Price returns, dividends excluded.
Quarterly results
ESEF annual reports carry no quarters: the results are annual (below).
E/P over time
the price (USD) and the reports are in different currencies
E/P = trailing-12-month diluted EPS / price at quarter end. E/P is the inverse of P/E and stays defined when earnings are negative.
Fiscal years
| Fiscal year | ⚠ 2018 | 2019 | 2020 | ⚠ 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 278.7 m | 834.9 m | 478.1 m | 234.4 m | 241.2 m | 239.7 m | 275.6 m | 1.1 bn |
| Revenue YoY | — | +199.6% | −42.7% | — | +2.9% | −0.6% | +15.0% | +303.5% |
| Net income | -29.3 m | 149.8 m | -305.4 m | -103.2 m | -218.0 m | 211.7 m | 74.1 m | 320.9 m |
| Net income YoY | — | unavailable | −303.8% | — | unavailable | unavailable | −65.0% | +333.1% |
| Diluted EPS | -0.56 | 2.49 | -4.69 | -1.58 | -3.32 | 3.21 | 1.12 | 4.87 |
| Diluted EPS YoY | — | unavailable | −288.4% | — | unavailable | unavailable | −65.1% | +334.8% |
| net % | -10.5% | 17.9% | -63.9% | -44.0% | -90.4% | 88.3% | 26.9% | 28.9% |
| Free cash flow | -152.9 m | 3.2 bn | -469.9 m | -558.0 m | -527.9 m | -424.7 m | -336.7 m | -271.2 m |
The series breaks before 2018, 2021: earlier years come from the original reports of the issuer of that time, later years from a subsequent filing that restated the perimeter (a separation, discontinued operations). The year-on-year change across the break is not shown.
Reported results vs expectations
Loading…
Balance sheet & financial health
Fiscal year 2025 · 31 Dec 2025
- Cash
- 40.0 m EUR
- Financial debt
- unavailable EUR
- Net debt
- unavailable EUR
- Equity
- 3.2 bn EUR
- Total assets
- 3.4 bn EUR
- Debt / equity
- unavailable
- Current ratio
- 20.15x
- ROE
- 10.5%
- ROA
- 8.5%
- FCF margin
- -24.4%
Financial statements (source on every figure)
Revenue and net income (EUR)
Margins
Income statement · EUR
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Revenue | 478.1 m | 234.4 m | 241.2 m | 239.7 m | 275.6 m | 1.1 bn | SEC (XBRL)· 26 Mar 2026verified |
| Cost of revenue | — | 1.6 m | 12.1 m | — | 34.9 m | 29.7 m | SEC (XBRL)· 26 Mar 2026verified |
| Gross profit | — | 232.8 m ≈ | 229.2 m ≈ | — | 240.8 m ≈ | 1.1 bn ≈ | SEC (XBRL)· 26 Mar 2026derived |
| Research & development | 523.7 m | 320.5 m | 269.8 m | 241.3 m | 335.5 m | 459.4 m | SEC (XBRL)· 26 Mar 2026verified |
| Operating income | -178.6 m | -171.6 m | -131.1 m | -88.3 m | -188.3 m | 295.0 m | SEC (XBRL)· 26 Mar 2026verified |
| Pre-tax income | -309.8 m | -119.4 m | -70.8 m | 5.6 m | -3.1 m | 300.9 m | SEC (XBRL)· 26 Mar 2026verified |
| Income tax | 1.2 m | 1.4 m | 572.0 k | 9.6 m | -1.8 m | -18.6 m | SEC (XBRL)· 26 Mar 2026verified |
| Net income | -305.4 m | -103.2 m | -218.0 m | 211.7 m | 74.1 m | 320.9 m | SEC (XBRL)· 26 Mar 2026verified |
| Diluted EPS | -4.69 | -1.58 | -3.32 | 3.21 | 1.12 | 4.87 | SEC (XBRL)· 26 Mar 2026verified |
| Weighted average diluted shares | — | — | 65.7 m | 65.9 m | 65.9 m | 65.9 m | SEC (XBRL)· 26 Mar 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Revenue − Cost of revenue.
Balance sheet · EUR
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Cash | — | 807.9 m | 97.3 m | 34.5 m | 40.3 m | 40.0 m | SEC (XBRL)· 26 Mar 2026verified |
| Receivables | 148.4 m | 111.3 m | 40.4 m | 28.4 m | 47.5 m | 20.7 m | SEC (XBRL)· 26 Mar 2026verified |
| Inventories | 36.0 k | 20.6 m | 52.9 m | 74.0 m | 51.2 m | 22.5 m | SEC (XBRL)· 26 Mar 2026verified |
| Current assets | 5.4 bn | 4.9 bn | 4.2 bn | 3.9 bn | 3.3 bn | 3.1 bn | SEC (XBRL)· 26 Mar 2026verified |
| Property, plant & equipment, net | 68.3 m | 105.7 m | 126.7 m | 111.2 m | 105.4 m | 71.9 m | SEC (XBRL)· 26 Mar 2026verified |
| Goodwill | — | — | 69.8 m | 69.6 m | 70.0 m | — | SEC (XBRL)· 27 Mar 2025verified |
| Intangibles (excl. goodwill) | 67.6 m | 60.1 m | 146.4 m | 127.9 m | 164.9 m | 848.0 k | SEC (XBRL)· 26 Mar 2026verified |
| Total assets | 5.7 bn | 5.2 bn | 4.7 bn | 4.4 bn | 4.1 bn | 3.4 bn | SEC (XBRL)· 26 Mar 2026verified |
| Accounts payable | 175.6 m | 137.6 m | 148.7 m | 135.2 m | 98.9 m | 104.6 m | SEC (XBRL)· 26 Mar 2026verified |
| Current liabilities | 635.3 m | 566.5 m | 522.5 m | 428.2 m | 335.1 m | 152.9 m | SEC (XBRL)· 26 Mar 2026verified |
| Total liabilities | 3.0 bn | 2.5 bn | 2.2 bn | 1.6 bn | 1.2 bn | 170.7 m | SEC (XBRL)· 26 Mar 2026verified |
| Equity | 2.7 bn | 2.6 bn | 2.5 bn | 2.8 bn | 2.9 bn | 3.2 bn | SEC (XBRL)· 26 Mar 2026verified |
| Shares outstanding at year end | 65.4 m | 65.6 m | 65.8 m | 65.9 m | 65.9 m | 65.9 m | SEC (XBRL)· 26 Mar 2026verified |
Cash flow · EUR
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -427.3 m | -503.8 m | -500.5 m | -406.0 m | -320.0 m | -257.5 m | SEC (XBRL)· 26 Mar 2026verified |
| Capex | 42.5 m | 54.2 m | 27.4 m | 18.7 m | 16.7 m | 13.7 m | SEC (XBRL)· 26 Mar 2026verified |
| Free cash flow | -469.9 m ≈ | -558.0 m ≈ | -527.9 m ≈ | -424.7 m ≈ | -336.7 m ≈ | -271.2 m ≈ | SEC (XBRL)· 26 Mar 2026derived |
| Investing cash flow | 757.3 m | 541.2 m | -1.2 bn | 71.2 m | 220.6 m | 288.8 m | SEC (XBRL)· 26 Mar 2026verified |
| Financing cash flow | 22.0 m | -3.9 m | -1.5 m | -5.0 m | -4.9 m | -3.3 m | SEC (XBRL)· 26 Mar 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Operating cash flow − Capex.
Computed indicators
Growth
Profitability
Returns
Balance sheet
Liquidity
Cash
Efficiency
Market and valuation
1 indicators that do not apply to the sector.
Valuation
olivLaw classification
- indicators available: 4 of at least 6
- score weight coverage: 25.0% of at least 60%
A scoring methodology on indicators and valuation, not investment advice.
Closing price
04 Nov 2026Source: olivLaw, closing series
Market cap: unavailable
Price and reporting are in different currencies; market indicators are unavailable.
Key indicators
Coverage and freshness
Score by group
25% · Insufficient data
Estimated value range
The combined range = the median of the valid methods' low, central and high values; it is not a probability interval and does not cover every result. Envelope of all methods: 72.79 – 212.53 EUR.
Valuation assumptions are editorial choices, not measured; beta is not measured.
Method ranges (EUR per share)
— — Mid · ▏ Price
Valuation methods
- DCF (discounted cash flow)unavailable · input data missing
- Peers: EV/EBITDAunavailable · net debt missing: EV cannot be bridged to equity (missing debt is not zero)
- Peers: P/E72.79 – 212.53 (Mid 141.95)14 companies used · median multiple 29.1x · quartiles 14.9x – 43.6xABBV, ABT, ALNY, AUPH, BMY, JNJ, LLY, NATR, PFE, REGN, RPRX, UTHR, VRTX, ZTS
- Dividend discount (DDM)unavailable · the company pays no dividend: a dividend model needs an explicit initiation assumption
Classification (SIC) comparables group by industry code, not by economic activity; the direct group is an editorial selection by activity. Members' multiples are on their own trailing twelve months, at their own latest close.
Assumptions (illustrative, editorial)
- Risk-free rate
- 3.0%
- Equity risk premium
- 5.5%
- Beta (default)
- 1.00
- Cost of equity
- 8.5%
- Terminal growth
- 2.0%
Factor scorecard
Insufficient data
Minimum-evidence gate: indicators available: 4 of at least 6; score weight coverage: 25.0% of at least 60%
| Factor | Value | Score | Weight used |
|---|---|---|---|
| ROIC · Quality | unavailable | unavailable | — |
| Net margin · Quality | 28.9% | 85 (vs peers) | 25% |
| FCF conversion · Quality | -84.5% | 0 (on a fixed band) | 25% |
| Revenue CAGR 3Y · Growth | 66.4% | 100 (on a fixed band) | 33% |
| EPS CAGR 3Y · Growth | unavailable | unavailable | — |
| Net debt / EBITDA · Balance sheet | unavailable | unavailable | — |
| Interest coverage · Balance sheet | unavailable | unavailable | — |
| Current ratio · Balance sheet | 20.1x | 100 (on a fixed band) | 17% |
| P/E (TTM) · Valuation | unavailable | unavailable | — |
| EV/EBITDA · Valuation | unavailable | unavailable | — |
| FCF yield · Valuation | unavailable | unavailable | — |
| Shareholder yield (distributions) · Returns | unavailable | unavailable | — |
| Payout ratio (FCF) · Returns | unavailable | unavailable | — |
Factors without a value were dropped; the remaining weights were renormalised.
Score groups
- Balance sheet· partial100/100 · 1/3 factors with a value
- Growth· partial100/100 · 1/2 factors with a value
- Quality43/100 · 2/3 factors with a value
- Returns· partialunavailable · 0/2 factors with a value
- Valuation· partialunavailable · 0/3 factors with a value
A «partial» group is computed from under half of its weight or from one factor: it is not a full assessment of the group.
Memo
GALAPAGOS NV (LKFT). Latest full fiscal year: 2025; data up to 2025-12-31.
Figures computed from the financial statements: revenue 1.1 bn EUR in 2025; YoY growth 303.5%; net margin 28.9%; ROE 10.5%.
The estimated value range is 72.79–212.53 EUR per share (median of 1 methods, agreement: single method); assumptions are illustrative. The range is the median of the methods' low, central and high values, not a probability interval.
Insufficient data for a verdict (indicators available: 4 of at least 6; score weight coverage: 25.0% of at least 60%).
Text generated deterministically from the figures shown; no language model. Not investment advice.
What supports the thesis
- Net margin: 28.9%
- Revenue CAGR 3Y: 66.4%
- Current ratio: 20.1x
What contradicts it
- FCF conversion: -84.5%
Not assessed (insufficient data or a ratio without meaning): ROIC, EPS CAGR 3Y, Net debt / EBITDA, Interest coverage, P/E (TTM), EV/EBITDA, FCF yield, Shareholder yield (distributions), Payout ratio (FCF).
Versus the vertical median
Pharmaceutical Preparations (SIC 2834) · same industry (4-digit SIC) · compared with 39 companies
Multiples and returns vs the median
Price rebased to 100 (monthly, 5 years)
Companies in the vertical
| Market cap | P/E | ROE | Net margin | Revenue YoY | 1A / 3A | |
|---|---|---|---|---|---|---|
| LLYEli Lilly And Company | 1,334.0 bn | 46.0 | 86.1% | 31.9% | +44.7% | +32% / +140% |
| JNJJohnson & Johnson | 665.2 bn | 41.9 | 20.0% | 16.2% | +6.0% | +34% / +79% |
| ONCBeone Medicines Ltd. | 558.4 bn | 869.9 | 14.7% | 10.7% | +40.2% | +11% / +102% |
| ABBVAbbVie Inc. | 521.1 bn | 50.7 | — | 15.7% | +8.6% | +29% / +107% |
| MRKMerck & Co., Inc. | 370.7 bn | 154.7 | 5.1% | 3.6% | +1.3% | +43% / +47% |
| ABTAbbott Laboratories | 200.1 bn | 43.0 | 9.2% | 9.7% | +5.7% | −10% / +11% |
| PFEPfizer Inc | 175.5 bn | 43.9 | 4.4% | 6.3% | −1.6% | +20% / +1% |
| VRTXVertex Pharmaceuticals Inc | 139.2 bn | 35.3 | 20.8% | 30.7% | +8.9% | +27% / +55% |
| BMYBristol-Myers Squibb Company | 131.2 bn | 14.2 | 44.1% | 18.5% | −0.2% | +30% / +30% |
| TEVATeva Pharmaceutical Industries Limited | 48.8 bn | 97.4 | 6.6% | 3.6% | +4.3% | +56% / +326% |
| ZTSZoetis Inc. | 36.9 bn | 14.7 | 64.4% | 27.5% | +2.3% | −30% / −50% |
| ROIVRoivant Sciences Ltd. | 27.6 bn | — | -6.2% | -3,535.0% | −71.6% | +84% / +300% |
| RPRXRoyalty Pharma plc | 26.2 bn | 47.7 | 6.9% | 25.7% | +5.1% | +69% / +150% |
| UTHRUnited Therapeutics Corporation | 25.9 bn | 23.0 | 19.1% | 38.6% | +10.6% | +25% / +154% |
| INSMInsmed Inc | 24.1 bn | — | -72.5% | -39.9% | +66.7% | −47% / +340% |
| VTRSViatris Inc. | 22.1 bn | — | -23.6% | -23.9% | −3.0% | +80% / +109% |
| ALNYAlnylam Pharmaceuticals, Inc. | 21.6 bn | 8.1 | 126.6% | 52.8% | +65.2% | −64% / −4% |
| ORKAOruka Therapeutics, Inc. | 6.7 bn | — | -18.2% | — | unavailable | +237% / +364% |
| IONSIonis Pharmaceuticals, Inc. | 6.7 bn | — | -105.5% | -64.7% | +33.8% | −51% / −19% |
| IDYAIDEAYA Biosciences, Inc. | 3.1 bn | — | -38.5% | -1,149.6% | +3,024.4% | −9% / +3% |
| RADXRadiopharm Theranostics Limited | 3.1 bn | — | -109.2% | -1,055.3% | +1,114.3% | −81% / unavailable |
| AUPHAurinia Pharmaceuticals Inc. | 2.3 bn | 7.5 | 61.4% | 97.7% | +20.4% | +6% / +98% |
| LKFTGalapagos NV | 2.2 bn | 7.0 | 10.5% | 28.9% | +303.5% | +12% / −8% |
| QUREuniQure N.V. | 1.6 bn | — | -89.0% | -1,154.8% | −40.6% | −16% / +240% |
| URGNUroGen Pharma Ltd. | 1.4 bn | — | — | -26.3% | +21.4% | −0% / +118% |
1- and 3-year price returns: for LKFT from daily closes (the same as the performance table), for the other companies from month-end closes.
olivLaw engine forecast
The world engine ran after the company's latest material disclosure. Probabilities are of TOUCHING a level within the horizon (not closing there) and sit next to the random walk (p_rw), the no-information benchmark.
The engine has no published run for this company yet.
Valuation scenarios (editable assumptions)
Illustrative scenarios
Scenarios are not available. input data missing
AI analysis
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
Possibly outdated: the newest document it read is from 26 Mar 2026; since then the company filed 6-K (04 Nov 2026), 6-K (02 Nov 2026), 6-K (20 Oct 2026), 6-K (15 Oct 2026), 6-K (13 Oct 2026), 6-K (09 Oct 2026).
In brief
Galapagos NV is a Belgian biotechnology company redirecting its activity after deciding to wind down its cell therapy operations and focus on acquisitions and development partnerships. The timing matters because 2025 revenues were dominated by the release of deferred income from the Gilead agreement, while the company now relies on a sizeable financial portfolio and a single remaining clinical program, GLPG3667 1.
SWOT
Strengths
- The company has substantial financial resources and a profile that allows it to pursue acquisitions without the constraints of legacy infrastructure 1.
- Future royalty and earn-out inflows linked to Jyseleca provide a relatively predictable long-term cash flow 1.
- The company holds equity stakes in private biotechnology companies and real estate that could be monetised 1.
Weaknesses
- The company has a limited operating history under its current strategy, which makes its future prospects difficult to assess 1.
- The clinical pipeline has been reduced to a single key programme, and the SLE study did not meet its primary endpoint 1.
- The company has incurred significant operating losses in most years and expects losses to continue for the foreseeable future 1.
Opportunities
- If well-supported clinical assets are identified, business development transactions could rebuild the portfolio and create new value 1.
- GLPG3667 could attract partners if final GALACELA data prove favourable 1.
- The company is exploring expansion into other severe autoimmune diseases with significant unmet medical need 1.
Threats
- If strategic transactions are not concluded, the company could remain with a limited portfolio and continuing operating costs 1.
- Closing the cell therapy activities and reducing staff could affect the company's reputation and its relations with employees and local authorities 1.
- If additional funding is not available on acceptable terms, the company could be forced to relinquish rights to its assets 1.
Risks
- Limited operating historyhigh
The company has repeatedly changed its strategic direction, making future results hard to anticipate, and the 2025 profit was driven by a non-recurring release of revenue 1.
- Need for additional fundinghigh
The company may require additional capital for transactions and clinical development, which might be available only on unfavourable terms with dilution for shareholders 1.
- Clinical programme failurehigh
If final data from the GLPG3667 studies are unfavourable, the company could be left without a significant clinical asset and without clear commercial prospects 1.
- Costs and risks of the wind-downmedium
Closing cell therapy involves restructuring, possible litigation and obligations toward Gilead and other parties, which could affect financial results 1.
- Financial sector risklow
Events affecting financial institutions could affect the company's access to funds or the ability of its suppliers and partners to meet their obligations 1.
Investment thesis
What would need to be true (bull case)
- If development transactions are well chosen, the company's solid financial position could allow it to rebuild a valuable portfolio quickly without immediate reliance on external funding 1.
- Royalty and earn-out receipts linked to Jyseleca could provide a stable long-term cash flow supporting the strategy 1.
- If final GALACELA results are favourable, GLPG3667 could become a focal point of interest for partners with significant development value 1.
What would break the thesis
- If strategic transactions are not concluded, the company could remain with few revenue-generating assets and continuing operating losses 1.
- Revenues in 2025 were largely non-recurring, and without a commercial product, future financial performance could be hard to forecast 1.
- If clinical programmes fail to demonstrate their value, the company's substantial capital could be consumed without generating a meaningful return for shareholders 1.
What to watch
- Final GALACELA lupus results at Week 48Q2 2026
- Completion of the cell therapy wind-downQ3 2026
- Announcement of strategic business development transactions2026
- Decision on strategic options for GLPG3667next 10-K
Products, market & competition
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
Possibly outdated: the newest document it read is from 26 Mar 2026; since then the company filed 6-K (04 Nov 2026), 6-K (02 Nov 2026), 6-K (20 Oct 2026), 6-K (15 Oct 2026), 6-K (13 Oct 2026), 6-K (09 Oct 2026).
The business
The company describes its strategy as built to identify, acquire and advance medicines for serious diseases, prioritising oncology and immunology and inflammation with a modality-agnostic approach 1. In fiscal 2025, total net revenues were €1,112.2 million, of which €1,069.0 million came from the release of deferred income tied to the Gilead agreement, and net profit was €320.9 million 1. The company stated that, excluding these non-recurring items, it does not expect significant revenues beyond potential milestone and earn-out payments from Jyseleca 1.
In January 2026 the Board decided to wind down cell therapy activities, affecting approximately 365 employees across Europe, the U.S. and China, with the closure of the Leiden, Basel, Princeton, Pittsburgh and Shanghai sites. The wind-down is expected to be substantially completed by the end of the third quarter of 2026, after which GLPG3667 will be the only product in the pipeline 1.
The company transferred its Jyseleca business to Alfasigma in early 2024, receiving an upfront payment of €50 million and entitlement to potential milestone payments of €120 million, as well as earn-outs on European sales expected to continue into the mid-2030s 1.
Segments
Immunology and inflammation (GLPG3667)
GLPG3667 is an investigational reversible and selective TYK2 inhibitor in Phase 2 studies in dermatomyositis and systemic lupus erythematosus. In the GALARISSO dermatomyositis study the primary endpoint was met at a 10% significance threshold, while in the GALACELA lupus study the primary endpoint did not reach statistical significance 1. The company is now evaluating all strategic options for this programme 1.
CAR-T cell therapy (being wound down)
The GLPG5101 (CD19) and GLPG5301 (BCMA) programmes were in Phase 1/2 studies and are being terminated early, with last patient visits expected at the end of May 2026. Patients are expected to roll over into the long-term safety study HESPERIA 1.
Market context
The sources reviewed do not describe the size of the global market for the therapies the company develops. The company states it focuses on serious diseases with unmet medical need, particularly in oncology and immunology, where its strategy relies on acquisitions and partnerships rather than an existing commercial market 1.
The company holds substantial financial assets that allow it to pursue business development without immediate reliance on external funding. However, it warns that it will require significant additional capital to complete strategic transactions and clinical development, and that this depends on capital market conditions 1.
Trends
- Pivot toward business developmentmixed
The company has shifted its strategy toward transformational transactions and acquisitions of advanced clinical assets, which could speed up portfolio rebuilding if suitable assets are found 1.
- Decline of the historical commercial businessheadwind
Jyseleca revenues were transferred, and the company no longer has a commercial product, so future performance depends on new acquisitions or payments under existing agreements 1.
- Mixed clinical results in I&I programmesmixed
Data from the GALARISSO and GALACELA studies were mixed, which may influence the appeal of GLPG3667 to potential partners, depending on final GALACELA data 1.
- Cell therapy wind-downmixed
Closing cell therapy activities could reduce long-term operating costs, but it also brings restructuring costs and the loss of a portfolio that was once a strategic pillar 1.
Competitive position
The supplied source does not explicitly name direct competitors. The company operates in an area where acquisitions of clinical assets and development partnerships are contested by other investors and biotechnology companies, and its prospects depend on its ability to secure suitable assets 1.
The company aims to differentiate itself by selecting programmes with clinical proof-of-concept and by its financial capacity to act quickly, but the market for acquisitions remains competitive 1.
- Gilead SciencesGILD
Partner under the OLCA collaboration and former holder of option rights on the company's programmes; waived its rights over the cell therapy business 1.
- Alfasigma S.p.A.
Acquirer of the Jyseleca business, which took over the rights and commercial activities associated with the product 1.
- Onco3R Therapeutics BV
Partner that acquired several immunology and oncology assets, including a SIK inhibitor, alongside a convertible loan facility 1.
- Other CAR-T cell therapy developers
Companies active in the same cell therapy areas, whose presence influences the acquisition and partnership potential of the discontinued programmes 1.
Links, dependencies and risks
Who the company is tied to, from its own SEC filings (customers, suppliers, production, partners, competitors, countries, regulation), from the 5 %+ holders' statements (13D/13G) and from what other companies say about it. Click a node for its evidence; on a listed company the graph moves to it.
Loading the links…
News & filings
In the press
- Balenele albastre au dispărut din Galapagos. El Niño a încălzit apa oceanuluiAntena 3 CNN · 03 Nov 2026 · RO
- Diego a fost trimis în Galapagos după ce a trăit 30 de ani la zoo. A devenit tată pentru 800 de puiAntena 3 CNN · 26 Oct 2026 · RO
- Scientists alarmed as super El Niño collides with 'strange uptick' in Galapagos iguana traffickingPhys.org · 14 Oct 2026 · EN
- Povestea uimitoare a „țestoaselor extraterestre”: cum au revenit pe insula din Galapagos, de unde dispăruseră timp de două secoleAdevărul · 20 Sept 2026 · RO
- Țestoasele „extraterestre” s-au întors pe insula din Galapagos de unde au dispărut în urmă cu 150 de aniAntena 3 CNN · 20 Sept 2026 · RO
- 9 Standout Galapagos Cruises for Sailing the Bucket-List Wildlife DestinationConde Nast Traveler · 16 Sept 2026 · EN
- El Nino amenință paradisul unic din Galapagos. Populațiile de animale ar putea scădea cu cel puțin 20%Digi24 · 12 Sept 2026 · RO
- Doar 14 țestoase uriașe mai rămăseseră pe o insulă din Galapagos. Apoi l-au găsit pe masculul Diego într-un zoo și acum sunt 2.300Antena 3 CNN · 31 Aug 2026 · RO
- Experții au folosit „capre Iuda” care și-au vânat propria specie. Și așa au fost salvate țestoasele de GalapagosAntena 3 CNN · 06 Aug 2026 · RO
- O specie rară de rechin, observată în Galapagos după mai bine de 20 de ani. Descoperirea îi surprinde pe cercetătoriMediafax · 30 Jul 2026 · RO
- Nasa images show wildfire damage to island dubbed ‘Galapagos of California’The Guardian World · 27 May 2026 · RO
The latest news item in our archive is from 03 Nov 2026; the newest SEC filing is from 04 Nov 2026. The press archive comes from the RSS feeds we follow and does not necessarily cover the latest event — the filings alongside do.
SEC filings
- Current report (foreign issuer)04 Nov 2026
- Current report (foreign issuer)02 Nov 2026
- Current report (foreign issuer)20 Oct 2026
- Current report (foreign issuer)15 Oct 2026
- Current report (foreign issuer)13 Oct 2026
- Current report (foreign issuer)09 Oct 2026
- Current report (foreign issuer)06 Oct 2026
- Current report (foreign issuer)29 Sept 2026
- Current report (foreign issuer)23 Sept 2026
- Current report (foreign issuer)15 Sept 2026
Sources
- [1] Form 20-F, fiscal year ended 2025-12-31 · SEC / Galapagos NV · 26 Mar 2026
Figures computed by olivLaw from SEC filings and closing prices; the qualitative analysis is AI-generated from cited sources. Not investment advice.